PMP22 and Charcot-Marie-Tooth disease type 1A: This lipid supplementation bypassed the inefficient expression of genes for lipid synthesis in PMP22 transgenic Schwann cells and resulted in improved myelin biosynthesis and reduced neuropathic symptoms in a CMT1A rat model.